Table 2 Test characteristics
|  | Total Cohort n = 159 |
|---|---|
Functional test type | |
 Exercise stress echocardiography | 62 (39.0%) |
 ETT-ECG | 35 (22.0%) |
 Exercise stress SPECT | 27 (17.0%) |
 Stress PET | 19 (12.0%) |
 Pharmacologic stress SPECT | 6 (3.8%) |
 Level I CPET | 4 (2.5%) |
 Exercise converted to pharmacologic stress SPECT | 3 (1.9%) |
 Stress cardiac MRI | 2 (1.3%) |
 Dobutamine stress echocardiography | 1 (0.6%) |
Functional test indication | |
 Asymptomatic CAD screening | 77 (48.4%) |
 Dyspnea | 34 (21.4%) |
 Chest pain | 26 (16.4%) |
 Pre-op | 12 (7.6%) |
 Syncope | 3 (1.9%) |
 Palpitations | 2 (1.3%) |
 Other | 5 (3.1%) |
CT chest type | |
 CT Chest without Contrast | 55 (34.6%) |
 CT Chest with Contrast | 43 (27.0%) |
 FDG PET/CT | 21 (13.2%) |
 Stress PET | 19 (12.0%) |
 CT-PE | 17 (10.7%) |
 CCTA | 2 (1.3%) |
 Other | 2 (1.3%) |
CT chest indication | |
 Lymphoma follow up | 58 (36.5%) |
 Dyspnea | 26 (16.4%) |
 Transmission scan for stress PET | 17 (10.7%) |
 Lung cancer screening | 15 (9.4%) |
 Pulmonary nodule follow up | 11 (6.9%) |
 Other cancer | 9 (5.7%) |
 Mesothelioma | 3 (1.9%) |
 Sarcoma | 3 (1.9%) |
 Breast | 1 (0.6%) |
 Esophageal | 1 (0.6%) |
 Laryngeal | 1 (0.6%) |
 Chest pain | 6 (3.8%) |
 Pre-op | 2 (1.3%) |
 Other | 15 (9.4%) |